BackgroundType 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances β-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to evaluate the effect of imatinib on fasting plasma glucose in subjects with normal fasting glucose, subjects with impaired fasting glucose and in subjects with type 2 diabetes mellitus.MethodsWe identified 284 subjects diagnosed with chronic myeloid leukemia or gastrointestinal stromal tumors from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran database. 106/284 subjects were treated with imatinib. We compared the effect of imatinib on fasting plasma glucose after 1 and 6 months of treatment. We used ANOVA test of repeated samples to determine statistical significance in fasting plasma glucose before imatinib treatment and the follow-up. Statistical analysis was performed with Statistical Package for the Social Sciences v22.ResultsWe included a total of 106 subjects: 76 with fasting plasma glucose concentrations < 100 mg/dL (normal FG), 19 subjects with fasting plasma glucose concentrations ≥100 mg/dL (impaired fasting glucose), and 11 subjects with ≥126 mg/dL (type 2 diabetes mellitus). We found a significant increase in fasting plasma glucose concentration in the normal fasting glucose group (p = 0.048), and a significant decrease in fasting plasma glucose concentration in the type 2 diabetes mellitus group (p = 0.042). In the impaired fasting glucose group, we also found a tendency towards a decrease in fasting plasma glucose (p = 0.076). We identified 11 subjects with type 2 diabetes mellitus, of whom, 7 (64%) had a reduction in their fasting plasma glucose concentrations after 6 months. A significant glycosylated hemoglobin reduction (p = 0.04) was observed.ConclusionSubjects with chronic myeloid leukemia or gastrointestinal stromal tumor with type 2 diabetes mellitus had a significant reduction in fasting plasma glucose and glycosylated hemoglobin at 1 and 6 months while using imatinib.Electronic supplementary materialThe online version of this article (10.1186/s12902-018-0303-x) contains supplementary material, which is available to authorized users.

No abstract

Soft tissue tumors account for less than 0.1% of colon and rectum malignant neoplasms. Epithelioid sarcoma is a subtype of undifferentiated soft tissue neoplasia that makes up 1% of this category; it is characterized by a slow progression, commonly affecting young male adults, with little or no response to chemotherapy and radiotherapy, leaving surgical resection their main therapeutic option to reduce recurrence. We here present the case of a 71-year-old male patient admitted for major rectorrhagia after evacuations and anal pain. During physical examination, a posterior anal sphincter induration was noted, which extended to the puborectal muscle. Anoscopy was performed where a thrombosed hemorrhoidal bundle was detected adjacent to a mass. In the later biopsy with immunohistochemistry, a proximal ulcer type, histological grade three epithelioid sarcoma was diagnosed. Subsequently, traditional abdominal perineal resection with colostomy was performed, resulting in favorable postoperative evolution and discharge after six days of the procedure. Keywords: soft tissue tumors; epithelioid sarcoma.

The aim of this literature review is to summarize techniques used to prevent postoperative visual pathway complications during parietal glioma resection involving optic radiations (OR), focusing on the use of virtual reality (VR) headset during awake patient surgery. We searched the Medline database for literature between the years of 1970 and 2021. Only results that included the use of AC for sensory mapping were included for evaluation. The search was limited to studies published in English and humans as subjects. Only studies that reported patient groups treated with either parietal glioma surgery under general anesthesia or awake conditions were included. Articles describing deep brain stimulation as the therapy were excluded. The variables initially selected for analysis included the length of surgery, length of hospital stay, extent of resection, cost, mortality, and neurological morbidity. Cost was later removed from the studied variables because too few studies reported it. No commentaries or reviews were included. Gliomas are the most common primary brain tumors located mainly in the cerebral cortex. 17% are found in the parietal lobe, which is a convergence area for multiple stimulus integration. After surgical resection of this lobe, patients may develop postoperative verbal, linguistic and visual field deficits. The gold standard treatment for these tumors is surgical resection. The main technique to preserve functional pathways is by intraoperative monitoring, for which different tools have been developed in the past years. Surgeons can test and preserve important tracts, such as the visual pathway. Intraoperative ultrasound has shown to be an excellent, accessible, and affordable intraoperative monitoring tool. Magnetic resonance imaging-based tractography and reality-based brain mapping allow not only intraoperative monitoring, but also create a preoperative plan by demarcating the structures and margins of the tumor prior to and during surgery, increasing success rate in maximum resection.